Table 2.
The flash visual evoked potential (VEP) of indirect traumatic optic neuropathy (ITON) patients before and 3 months after endoscopic trans-ethmosphenoid optic canal decompression (ETOCD) and the conservative treatment
| Variables | Groups | Time points | ||
|---|---|---|---|---|
| Pre-treatment | Post-treatment | P | ||
| Latent period of N1 (ms) | ETOCD-Improved VA | 69.60 ± 14.44 | 50.21 ± 20.69 | < 0.001* |
| ETOCD-No improved VA | 76.00 ± 19.44 | 54.01 ± 18.51 | < 0.001* | |
| P† | 0.085 | 0.308 | ||
| ETOCD-Total | 71.13 ± 18.92 | 51.12 ± 16.74 | < 0.001* | |
| Conservative treatment | 69.70 ± 19.17 | 66.24 ± 17.58 | 0.211 | |
| P# | 0.756 | 0.001* | ||
| Latent period of N2 (ms) | ETOCD-Improved VA | 111.57 ± 20.37 | 82.01 ± 18.35 | < 0.001* |
| ETOCD-No improved VA | 114.51 ± 11.25 | 107.43 ± 10.62 | 0.428 | |
| P† | 0.245 | < 0.001* | ||
| ETOCD-Total | 111.80 ± 19.69 | 87.51 ± 14.13 | < 0.001* | |
| Conservative treatment | 109.25 ± 15.98 | 100.48 ± 24.59 | 0.050 | |
| P# | 0.714 | < 0.001* | ||
| Latent period of P1 (ms) | ETOCD-Improved VA | 89.01 ± 16.90 | 65.63 ± 18.74 | < 0.001* |
| ETOCD-No improved VA | 92.11 ± 11.09 | 90.94 ± 22.43 | 0.347 | |
| P† | 0.301 | 0.009* | ||
| ETOCD-Total | 89.50 ± 16.77 | 72.30 ± 27.53 | < 0.001* | |
| Conservative treatment | 88.47 ± 15.36 | 85.57 ± 25.36 | 0.397 | |
| P# | 0.847 | 0.013* | ||
| Latent period of P2 (ms) | ETOCD-Improved VA | 128.31 ± 25.51 | 128.42 ± 26.02 | 0.987 |
| ETOCD-No improved VA | 129.77 ± 15.19 | 130.93 ± 23.98 | 0.765 | |
| P† | 0.715 | 0.662 | ||
| ETOCD-Total | 128.65 ± 20.81 | 129.02 ± 24.82 | 0.207 | |
| Conservative treatment | 125.69 ± 22.58 | 123.89 ± 26.71 | 0.514 | |
| P# | 0.152 | 0.101 | ||
| Amplitude of P1 (μV) | ETOCD-Improved VA | 3.42 ± 1.41 | 6.38 ± 3.58 | < 0.001* |
| ETOCD-No improved VA | 4.48 ± 2.31 | 7.20 ± 4.09 | 0.001* | |
| P† | 0.137 | 0.108 | ||
| ETOCD-Total | 3.67 ± 2.71 | 6.58 ± 4.16 | < 0.001* | |
| Conservative treatment | 4.01 ± 2.16 | 4.28 ± 3.12 | 0.769 | |
| P# | 0.514 | < 0.001* | ||
| Amplitude of P2 (μV) | ETOCD-Improved VA | 4.60 ± 1.91 | 6.92 ± 3.02 | < 0.001* |
| ETOCD-No improved VA | 4.92 ± 1.37 | 4.43 ± 2.83 | 0.291 | |
| P† | 0.196 | 0.006* | ||
| ETOCD-Total | 4.69 ± 1.46 | 6.07 ± 3.21 | < 0.001* | |
| Conservative treatment | 4.93 ± 2.47 | 4.81 ± 4.19 | 0.844 | |
| P# | 0.845 | 0.041* | ||
Data are the means plus/minus standard deviations. ETOCD, endoscopic trans-ethmosphenoid optic canal decompression; VA, visual acuity; P, P value between values of pre-treatment and post-treatment; P†, P value between improved VA group and no improved VA group after ETOCD; P#, P value between two groups treated with ETOCD and the conservation treatment; *P < 0.05